1-7 of 7
Sandra Close
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Baseline Prognostic Factors Do Not Predict End of Treatment Ctdna MRD Status and Have Limited Impact on MRD Prognostic Performance in DLBCL

Jordan S Goldstein, Mark Roschewski, Won-Seog Kim, Sang Eun Yoon, Seok Jin Kim, Jason R. Westin, Ryan C Lynch, Stefan K. Alig, Sandra Close, Jacob Chabon, Davide Rossi, Wyndham H. Wilson, David Kurtz, Ash A. Alizadeh
Journal: Blood
Blood (2024) 144 (Supplement 1): 651.
https://doi.org/10.1182/blood-2024-211068
Published: 2024
Journal Articles

Optimizing Circulating Tumor DNA Limits of Detection for DLBCL during First Line Therapy

Jordan Goldstein, Won Seog Kim, Sang Eun Yoon, Seok Jin Kim, Mark Roschewski, Jason Westin, Ryan C Lynch, Stefan K. Alig, Sandra Close, Jacob J. Chabon, Davide Rossi, Wyndham H Wilson, Maximilian Diehn, Ash A. Alizadeh, David M. Kurtz
Journal: Blood
Blood (2023) 142 (Supplement 1): 187.
https://doi.org/10.1182/blood-2023-187759
Published: 2023
Journal Articles

End-of-Treatment Response Assessment after Frontline Therapy for Aggressive B-Cell Lymphoma: Landmark Comparison of a Singular PET/CT Scan Versus Ultrasensitive Circulating Tumor DNA

Mark Roschewski, Liza Lindenberg, Esther Mena, Rahul Lakhotia, Christopher Melani, Seth M. Steinberg, Andre Schultz, Gregory Hogan, Jake J. Chabon, Sandra Close, Maximilian Diehn, Brian J. Sworder, David M. Kurtz, Ash A. Alizadeh, Wyndham H. Wilson
Journal: Blood
Blood (2023) 142 (Supplement 1): 192.
https://doi.org/10.1182/blood-2023-180007
Published: 2023
Journal Articles

Prognostic Utility of Minimal Residual Disease (MRD) after Curative Intent Induction Therapy for DLBCL: A Prospective Real-World Ctdna Study

Brian J. Sworder, Sang Eun Yoon, Seok Jin Kim, Andre Schultz, Gregory Hogan, Sandra Close, Jacob J. Chabon, Maximilian Diehn, David M. Kurtz, Ash A. Alizadeh, Won Seog Kim
Journal: Blood
Blood (2023) 142 (Supplement 1): 69.
https://doi.org/10.1182/blood-2023-187650
Published: 2023
Journal Articles

Phased Variants Allow Robust Profiling of Circulating Tumor DNA in Untreated Follicular Lymphomas

Ákos Nagy, Bence Bátai, Gregory Hogan, Jacob J. Chabon, Mikayla Troke, Lance Riley, Andre Schultz, Sandra Close, Maximilian Diehn, Donát Alpár, Botond Timár, Ash A. Alizadeh, David M. Kurtz, Csaba Bödör
Journal: Blood
Blood (2023) 142 (Supplement 1): 1626.
https://doi.org/10.1182/blood-2023-189824
Published: 2023
Journal Articles

Ultrasensitive MRD Profiling Predicts Outcomes in DLBCL after Frontline Therapy with Tafasitamab in Combination with Lenalidomide and R-CHOP

David M. Kurtz, Gregory J. Hogan, Andre Schultz, Katerina Kopeckova, Christian Kuffer, Derek Blair, Steve Wagner, Sandra Close, Maximilian Diehn, Jacob J. Chabon, Ash A. Alizadeh, Jason Westin
Journal: Blood
Blood (2022) 140 (Supplement 1): 3498–3499.
https://doi.org/10.1182/blood-2022-168378
Published: 2022
Journal Articles

MRD-Negativity As a Potential Surrogate Endpoint after Frontline DLBCL Therapy: Pooled Analysis of Trials & Implications for Clinical Trial Design

Mark Roschewski, David M. Kurtz, Jason Westin, Ryan C. Lynch, Charles Macaulay, Christian Kuffer, Gregory J. Hogan, Sandra Close, Jacob J. Chabon, Davide Rossi, Maximilian Diehn, Ash A. Alizadeh, Andre Schultz
Journal: Blood
Blood (2022) 140 (Supplement 1): 785–786.
https://doi.org/10.1182/blood-2022-167936
Published: 2022